FindMyRecallSubscribe
Class I: serious health riskTerminated

Eli Lilly & Glucagon Emergency Kit for Low Blood Sugar Recall

Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial

Eli Lilly & Company · Indianapolis, IN

Risk level
Class I
Reported by FDA
Oct 20, 2021
Recall ID
D-0009-2022
Check your lot numberHow we source this data

Summary

Eli Lilly & recalled Glucagon Emergency Kit for Low Blood Sugar starting Sep 24, 2021. The FDA classified it as Class I (serious health risk) and published enforcement report D-0009-2022 on Oct 20, 2021. Reason: SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration. Status: Terminated.

Why it was recalled

SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.

Product description

Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe. Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285; Glucagon, NDC: 0002-8031-01

Lot numbers, UPCs & expiration codes

Lot #: D239382D, Exp. Date April 2022

Where it was sold

Nationwide with the USA and Puerto Rico; Canada, Argentina, Costa Rica, Mexico

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0009-2022
Classification
Class I
Status
Terminated
Recall initiated
Sep 24, 2021
FDA report date
Oct 20, 2021
Quantity
19,174 syringes
Recall type
Voluntary: Firm initiated
Recalling firm
Eli Lilly & Company

Original FDA data

Every field from FDA enforcement report D-0009-2022, exactly as published.

Show all FDA fields
City
Indianapolis
State
IN
Status
Terminated
Country
United States
Event ID
88764
Address
839 S Delaware St
Code information
Lot #: D239382D, Exp. Date April 2022
Postal code
46225-1782
Report date
Oct 20, 2021
Product type
Drugs
Recall number
D-0009-2022
Classification
Class I
Recalling firm
Eli Lilly & Company
Product quantity
19,174 syringes
Termination date
Sep 6, 2024
Reason for recall
SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe. Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285; Glucagon, NDC: 0002-8031-01
Distribution pattern
Nationwide with the USA and Puerto Rico; Canada, Argentina, Costa Rica, Mexico
Recall initiation date
Sep 24, 2021
Initial firm notification
Press Release
Center classification date
Oct 14, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0009-2022, published Oct 20, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls